Home
 /
Papers
 /
Immunology
 /
Targeting RUNX1 in Macrophages Facilitates Cardiac Recovery
Preprint
Open access
V1
Top 1% · Validated by QED

Targeting RUNX1 in Macrophages Facilitates Cardiac Recovery

Junedh M. Amrute, Ada Zhu, Yun-Ling Pai +43 more
July 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.07.25.665779
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Immunology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By identifying RUNX1 as the epigenetic brake on cardiac recovery and proving its pharmacologic inhibition restores failing hearts, this work transforms organ recovery from an emergent phenomenon into a mechanistically defined, druggable process.

QED claims analysis

Summary

The transcription factor RUNX1 in cardiac macrophages orchestrates a conserved inflammatory gene regulatory network that impedes cardiac recovery, and its deletion or pharmacological inhibition promotes functional recovery in chronic heart failure through macrophage reprogramming that suppresses inflammation, reduces fibrosis, and promotes adaptive cardiomyocyte remodeling via a BRD4-regulated epigenetic mechanism.

See full analysis
Main Claim 1 –

RUNX1 Regulates Macrophage Transcriptional Programs Limiting Cardiac Recovery

Supporting evidence

  • BRD4 Activates RUNX1 via a Specific Upstream Enhancer Element
Main Claim 2 –

Macrophage Runx1 Deletion Promotes Functional Recovery in Chronic Heart Failure

Supporting evidence

  • RUNX1 Directly Controls a Conserved Inflammatory Regulon in Macrophages
  • Macrophage Runx1 Deletion Drives Non-Cell-Autonomous Cardiomyocyte Adaptation
  • Macrophage Runx1 Deletion Suppresses Pro-Fibrotic Fibroblast Programs
Main Claim 3 –

Pharmacologic RUNX1 Inhibition Promotes Cardiac Recovery In Vivo

Abstract

Despite advances in disease treatment, our understanding of how damaged organs recover and the mechanisms governing this process remain poorly defined. Here, we mapped the transcriptional and regulatory landscape of human cardiac recovery using single cell multiomics. Macrophages emerged as the most reprogrammed cell type. Deep learning identified the transcription factor RUNX1 as a key regulator of this process. Macrophage-specific Runx1 deletion recapitulated the human cardiac recovery phenotype in a chronic heart failure model. Runx1 deletion reprogrammed macrophages to a reparative phenotype, reduced fibrosis, and promoted cardiomyocyte adaptation. RUNX1 chromatin profiling revealed a conserved regulon that diminished during recovery. Mechanistically, the epigenetic reader BRD4 controlled Runx1 expression in macrophages. Chromatin activity mapping, combined with CRISPR perturbations, identified the precise regulatory element governing Runx1 expression. Therapeutically, small molecule Runx1 inhibition was sufficient to promote cardiac recovery. Our findings uncover a druggable RUNX1 epigenetic mechanism that orchestrates recovery of heart function.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?